Dawnrays Pharmaceutical (Holdings) Ltd

Dawnrays Pharmaceutical (Holdings) Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.22
  • Today's Change0.03 / 2.52%
  • Shares traded208.00k
  • 1 Year change-26.06%
  • Beta0.5252
Data delayed at least 15 minutes, as of Dec 07 2022 07:45 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company principally engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The Company operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines. The Finished Drugs segment is engaged in the manufacture and sale of finished drugs, including antibiotics finished drugs and non-antibiotics finished drugs.

  • Revenue in HKD (TTM)1.32bn
  • Net income in HKD405.25m
  • Incorporated2002
  • Employees1.06k
  • Location
    Dawnrays Pharmaceutical (Holdings) LtdUnits 3001-02, 30/F, CNT Tower, Wanchai Hong KongHKG
  • Phone+852 21119708
  • Fax+852 21119870
  • Websitehttp://www.dawnrays.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Lee's Pharmaceutical Holdings Ltd1.35bn-119.18m971.58m1.18k----9.200.7197-0.2024-0.20242.29--------1,023,466.00--17.88--23.7961.7365.23-9.3646.08---474.73--6.844.066.371,436.6851.146.57-11.44
Canbridge Pharmaceuticals Inc59.92m-1.10bn1.06bn141.00--1.88--17.70-12.50-12.500.2431.330.0773.604.95327,409.90-140.88---182.11--63.51---1,828.44--3.00-506.820.2359--158.98---27.30------
Genor Biopharma Holdings Ltd3.30m-970.72m1.23bn452.00--0.5213--373.67-1.94-1.940.00664.680.0010.01750.0295,153.68-30.50---33.43--73.38---29,412.99--8.33--0.0252---100.00--71.42------
Hbm Holdings Ltd230.89m-1.16bn1.32bn365.00--1.05--5.72-1.58-1.580.31471.640.0998--25.77599,708.60-50.15---57.13--99.31---502.40------0.2826---69.46--53.52------
Golden Throat Holdings Group Co Ltd847.31m181.73m1.33bn937.007.320.90755.941.570.24580.24581.151.980.42312.583.17904,281.909.078.5712.6412.0269.6972.6821.4518.782.38159.040.180656.2526.831.3321.8012.7644.8222.25
Transcenta Holding Limited50.56m-1.03bn1.39bn321.00--0.7522--27.46-2.33-2.330.11494.410.01941.654.56139,292.70-39.61---48.08--17.48---2,040.65--2.63-47.970.1908---37.96---441.82------
Zhaoke Ophthalmology Ltd0.00-338.26m1.50bn268.00--0.5443-----0.6244-0.62440.005.090.00----0.00-11.24---11.70-------------127.180.0247-------192.96------
Mabpharm Ltd34.01m-293.90m1.65bn389.00--3.01--48.50-0.0713-0.07130.00830.13290.03180.18753.9870,275.70-27.48---35.08--63.71---864.06--0.6451-32.370.205-------58.01------
Jacobson Pharma Corporation Ltd1.60bn177.67m1.70bn1.74k9.490.67674.481.070.09270.09270.83291.300.33162.915.60919,091.603.904.965.376.8838.8941.4111.7613.741.0516.360.322832.4610.354.902.28-0.186-7.1112.02
TOT Biopharm International Co Ltd262.45m-180.69m1.76bn355.00--3.86--6.71-0.3141-0.31410.45630.59520.32541.655.40778,793.70-22.41---34.33--73.14---68.85--0.8533-14.000.4296--239.36--9.46------
Dawnrays Pharmaceutical Holdings Ltd1.32bn405.25m1.78bn1.06k4.430.64643.771.350.26880.26880.87361.840.38392.397.001,236,350.0011.7211.4513.9513.8359.2658.7130.5329.602.3120.120.010542.6813.757.1733.586.1465.212.29
SinoMab Bioscience Ltd28.91m-354.36m1.88bn296.00--2.89--65.14-0.3587-0.35870.02930.63070.0264----102,170.20-32.38---34.63-------1,225.57-----6.780.3432-------135.07------
JW (Cayman) Therapeutics Co Ltd108.02m-949.43m1.99bn589.00--0.6859--18.46-2.34-2.340.26597.070.03043.112.83202,276.30-26.67---28.28--33.24---878.98--9.74-10.520.0545------57.79------
Essex Bio-Technology Ltd1.56bn323.01m2.03bn1.42k6.541.175.641.300.54270.54272.593.040.5751.873.021,128,434.0011.9414.0515.5818.5387.3882.6320.7621.202.0019.460.227215.5767.4316.1258.0320.4847.8724.31
Abbisko Cayman Ltd-100.00bn-100.00bn2.48bn192.00--0.8972----------3.95----------------------------0.0204-------156.14------
Immunotech Biopharm Ltd0.00-387.47m2.59bn267.00--3.40-----0.753-0.7530.001.480.00----0.00-33.66---37.53----------1.49-18.730.1291------19.32------
Data as of Dec 07 2022. Currency figures normalised to Dawnrays Pharmaceutical (Holdings) Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

10.69%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Sep 202191.68m6.12%
UBS Asset Management (Hong Kong) Ltd.as of 31 Aug 202237.04m2.47%
Dimensional Fund Advisors LPas of 03 Nov 202213.29m0.89%
Fidelity Investments Canada ULCas of 30 Sep 202211.01m0.73%
CATAM Asset Management AGas of 31 Mar 20213.23m0.22%
FIAM LLCas of 31 Oct 20222.35m0.16%
Dimensional Fund Advisors Ltd.as of 31 May 2022707.89k0.05%
LGT Capital Partners AG (Investment Management)as of 30 Nov 2021440.00k0.03%
Acadian Asset Management LLCas of 31 Oct 2022288.08k0.02%
FIL Investments Internationalas of 30 Jun 2022110.00k0.01%
More ▼
Data from 30 Sep 2022 - 01 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.